1381868-77-4

Basic information

• Product Name: 11β-(4-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)phenyl)-estra-4,9-diene-3,17-dione
• Synonyms: 11β-(4-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)phenyl)-estra-4,9-diene-3,17-dione
• CAS NO: 1381868-77-4
• Molecular Weight: 519.641
• Mol File: 1381868-77-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 11β-(4-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)phenyl)-estra-4,9-diene-3,17-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 11β-(4-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)phenyl)-estra-4,9-diene-3,17-dione(1381868-77-4)
• EPA Substance Registry System: 11β-(4-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)phenyl)-estra-4,9-diene-3,17-dione(1381868-77-4)

Safety Data

• Hazardous Substances Data: 1381868-77-4(Hazardous Substances Data)

Upstream product

• 134414-14-5 11beta-(4-hydroxyphenyl)-estra-4,9-diene-3,17-dione 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 
• 178685-33-1 8-azido-3,6-dioxaoctyl tosylate 
• 19249-03-7 triethylene glycol di-(p-toluenesulfonate) 
• 17878-42-1 4-((trimethylsilyl)oxy)phenyl magnesium bromide 
• 55180-24-0 3,3,17,17-di(ethylenedioxy)-5,10-epoxy-estr-9⁽¹¹⁾-ene 

Downstream Products

• 1236153-00-6 (8S,9R,11S,13S,14S)-11-(4-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)phenyl)-7,8,9,11,12,13,14,15,16,17-decahydro-13-methyl-17-oxo-6H-cyclopenta[a]phenanthren-3-yl acetate 
• 1236152-92-3 11β-(4-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)phenyl)estra-1,3,5(10)-triene-3,17β-diol 

Relevant articles and documents

Convergent synthesis of a steroidal antiestrogen-mitomycin C hybrid using "click" chemistry

A convergent synthesis of a novel estrogen receptor-targeted drug hybrid was developed based on structures of the potent anti-proliferative mitomycin C and the steroidal anti-estrogen RU 39411. The steroidal antiestrogen was prepared with an azido-triethylene glycoloxy linker while the mitomycin C derivative (porfirimycin) incorporated a complementary 7-N-terminal alkyne. The two components were ligated using the Huisgen [3 + 2] cycloaddition ("click") reaction. Preliminary biological assays demonstrated that the final hybrid compound retained both potent anti-estrogenic and anti-proliferative activities.

STEROIDAL ANTI-HORMONE HYBRIDS

Disclosed are novel compounds and compositions for inhibition of androgen and estrogen receptor signaling, methods for inhibiting androgen signaling, methods for inhibiting estrogen signaling, methods for inhibiting the interaction between a co-regulatory protein and an androgen or estrogen receptor, and methods for treating cancer.